Parameter | Patients above cut-off (%) | Patients below cut-off (%) | p values | Number of analyzed patients | Hazard ratios | ||
---|---|---|---|---|---|---|---|
Deterioration ≥ 10% | No deterioration | Deterioration ≥ 10% | No deterioration | ||||
Anti-CXCR3 antibodies | |||||||
FVC (%) | 25.0 | 75.0 | 59.3 | 40.7 | ≤ 0.01 | 59 | 0.32 |
FEV1 (%) | 23.5 | 76.5 | 71.1 | 28.9 | ≤ 0.001 | 72 | 0.22 |
DLCO-SB (%) | 36.4 | 63.6 | 63.6 | 36.4 | ≤ 0.05 | 55 | 0.47 |
DLCO/VA (%) | 42.4 | 57.6 | 70.4 | 29.6 | ≤ 0.05 | 60 | 0.38 |
Anti-CXCR4 antibodies | |||||||
FVC (%) | 22.2 | 77.8 | 70.0 | 30.0 | ≤ 0.001 | 47 | 0.2 |
FEV1 (%) | 33.3 | 66.7 | 78.6 | 21.4 | ≤ 0.001 | 61 | 0.27 |
TLC (%) | 33.3 | 66.7 | 64.7 | 35.3 | ≤ 0.05 | 44 | 0.33 |
DLCO-SB (%) | 43.3 | 56.7 | 75.0 | 25.0 | ≤ 0.05 | 46 | 0.46 |
DLCO/VA (%) | 39.4 | 60.6 | 82.4 | 17.6 | ≤ 0.001 | 50 | 0.24 |